SAN DIEGO, Sept. 30, 2014 /PRNewswire/ -- Organovo Holdings,
Inc. (NYSE MKT: ONVO) ("Organovo"), a three-dimensional biology
company focused on delivering breakthrough 3D bioprinting
technology, announced today that its exVive3D™ Human Liver
Model has been selected as a finalist in the Diagnostics &
Research Tools category for the 2014 Most Innovative New Product
Awards, sponsored by CONNECT. CONNECT, a regional program that
catalyzes the creation of innovative technology and life sciences
products in San Diego County,
continues its twenty-seven year tradition of honoring San Diego's leaders of innovation and
groundbreaking new products with the annual award.
Organovo's exVive3D™ Liver bioprinted human tissue models are
living, functional 3D human liver tissue constructs consisting of
primary human hepatocytes, stellate, and endothelial cell types
which are found in native human liver. The exVive3D™ Livers
are created using Organovo's proprietary 3D bioprinting technology
that results in functional living tissues containing precise and
reproducible architecture. The tissues can remain fully functional
and stable for at least 40 days. This model will initially be
made available through Organovo's contract research testing to
improve the predictive value for liver tissue specific toxicity or
ADMET marker assessment in later stage preclinical drug discovery
programs.
"For 27 years, CONNECT has been hosting the Most Innovative
Products (MIP) awards and each year the entrants just keep getting
better – this is one of the most competitive fields we've seen for
MIP yet," said Greg McKee, CEO of
CONNECT. "Annually, through the MIP awards CONNECT proudly presents
to the community the innovations and ground-breaking products being
developed in San Diego."
For the complete list of winners and other information please
visit the Most Innovative New Product Awards website.
About Organovo Holdings, Inc.
Organovo designs and
creates functional, three-dimensional human tissues for medical
research and therapeutic applications. The Company is collaborating
with pharmaceutical and academic partners to develop human
biological disease models in three dimensions. These 3D human
tissues have the potential to accelerate the drug discovery
process, enabling treatments to be developed faster and at lower
cost. The company plans to market its first product of a planned
portfolio offering, a 3D Human Liver Tissue for use in Toxicology
and other preclinical drug testing prior to the end of 2014, and
remains on track to bring this breakthrough technology to
customers. In addition to numerous scientific publications,
the Company's technology has been featured in The Wall Street
Journal, Time Magazine, The Economist, and numerous others.
Organovo is changing the shape of medical research and practice.
Learn more at www.organovo.com
About CONNECT
CONNECT is a regional program that
catalyzes the creation of innovative technology and life sciences
products in San Diego County by
creating an environment in which inventors and entrepreneurs have
access to the resources they need for success. Since 1985, CONNECT
has assisted in the formation and development of more than 3,000
companies and is now widely regarded as one of the world's most
successful organizations linking inventors and entrepreneurs with
the resources they need for commercialization of innovative
products. As a result, the program has been modeled in more than 50
regions around the world – most recently in New York City, Bogotá, Colombia and Saudi
Arabia. To learn more about CONNECT, please visit
www.connect.org or call 858.964.1300.
SOURCE Organovo Holdings, Inc.